| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01342341 | Alcohol Abuse | Drug: Parafon Forte | University of California, San Francisco | Phase 4 | 2011-04-01 | 2014-05-23 |
| NCT01933542 | Chlorzoxazone|Postoperative Pain | Drug: Placebo|Drug: Chlorzoxazone|Drug: Morphine|Drug: Zofran | Rigshospitalet, Denmark|Glostrup University Hospital, Copenhagen | Phase 4 | 2013-08-01 | 2015-09-16 |
| NCT02405104 | Osteoarthritis of Hip|Osteoarthritis, Knee | Drug: chlorzoxazone|Drug: Placebo|Procedure: THA|Procedure: TKA | Northern Orthopaedic Division, Denmark | Phase 4 | 2015-09-01 | 2015-12-10 |
| NCT01187862 | Cytochrome|Pharmacokinetics | Drug: caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam | University Hospital, Basel, Switzerland | Phase 1 | 2010-07-01 | 2015-04-16 |
| NCT00330434 | Alcohol Drinking|Depression|Smoking Cessation|Attention Deficit Disorder | Drug: Bupropion|Drug: Chlorzoxazone|Drug: Ethanol | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | | 2005-12-01 | 2008-04-07 |
| NCT00138684 | Insulin Resistance|Iron Overload | Procedure: venesection | Rennes University Hospital|Ministry of Health, France | Phase 2 | 2003-09-01 | 2012-05-18 |
| NCT00340535 | Normal Physiology | | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | | 2004-06-18 | 2017-01-24 |
| NCT02291666 | Type 2 Diabetes | Drug: CRCHUM-MT cocktail | Centre hospitalier de l'Universit de Montral (CHUM)|Canadian Institutes of Health Research (CIHR) | Phase 4 | 2015-04-01 | 2016-06-27 |
| NCT02654236 | Alcohol Consumption | Drug: Placebo|Drug: 10 mg Obeticholic Acid (OCA) | Suthat Liangpunsakul|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Intercept Pharmaceuticals|Indiana University | 2016-04-01 | 2016-11-04 |
